Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed a mid-stage study. The biotech says that it has learned from its setback and has now started a study for patients with multiple recurrent C. difficile infection that it’s hoping will serve as the pivotal Phase III for SER-109. That move — the most advanced microbiome study in the gut research world — was worth a $20 million milestone payment from its partners at Nestlé Health Science.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription